Natera (NASDAQ: NTRA) director trims 3,150 shares in a planned sale

What happened

Natera, Inc. (NASDAQ: NTRA) director and co-founder Jonathan Sheena sold 3,150 shares on 2026-10-21 for about $1.29 million.

The Form 4 says the sales ran from $406.50 to $416.67 per share, and the filing marks them as Rule 10b5-1 trades.

The reported prices were weighted averages across multiple sales within each lot.

After the sale, Sheena held 218,164 shares.

The filing was signed on 2026-10-23.

Key numbers

Metric	Latest	Change	Source
Shares sold	3,150 shares		SEC Form 4
Sale price range	$406.50 to $416.67 per share		SEC Form 4
Total sale value	about $1.29 million		SEC Form 4
Shares held after sale	218,164 shares	from 221,314 shares, -3,150 shares	Calculated from SEC Form 4

Read more: Natera (NTRA) stock analysis and investment case

Why it matters

OptimistFi's case is that Natera still has to prove clinical adoption and reimbursement can scale while cash generation improves.

This filing leaves that lens unchanged because the sale was under a Rule 10b5-1 plan adopted on December 12, 2025, and the shares were sold in eight lots on the same day.

The lot prices ran from $406.50 to $416.67 per share, which shows a staged execution rather than one block trade.

The eight lines ranged from 125 shares to 962 shares, another sign of routine execution.

The reported post-sale direct holding was 218,164 shares, and the filing also lists 8,250 shares held by Caraluna 1 Trust and 8,250 held by Caraluna 2 Trust, with beneficial ownership disclaimed.

The 3,150 shares were about 1.4% of the holding before the trade, so the move looks like a small trim rather than a broad exit.

The same filing also shows the pre-sale holding was 221,314 shares, giving investors a clean before-and-after read on the position size.

Taken together, the trade follows a preset plan rather than a one-off decision.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The next observable evidence is Natera's next quarterly report, which will show whether adoption, reimbursement and cash generation are continuing to move in line with the company's longer test.

A stronger report would matter more than this Form 4, while a weaker one would make the preplanned sale even less informative.

That report will be the clearer operating test for the investment case.

Investors will still need that release to judge whether the core thesis is improving.

More from OptimistFi

• NTRA stock: the Natera thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps